At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
In Brief
A Phase 2 clinical trial evaluating Dinutuximab, Laboratory Biomarker Analysis, and 2 other interventions for Metastatic Malignant Neoplasm in the Lung and 2 related conditions. Completed, enrolled 41 participants across 130 sites in 5 countries.
Detailed Summary
This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving dinutuximab with sargramostim may work better and kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Correlative studies
Given SC